21.94 USD
↗ 0.04 (0.18%)AT CLOSE (11:59 AM EDT)
Pelthos Therapeutics Inc.
PTHSAMEX • USD
22.08
↗ 0.14 (0.64%)
POST MARKET (AS OF 04:10 PM EDT)
Post Market
AS OF 04:10 PM EDT
22.08
↗ 0.14 (0.64%)
Market: CLOSED
PTHS is currently priced at $21.94. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (5755.6%) and a bullish Golden Cross on the moving averages. Valuation metrics suggest PTHS is trading at a discount to its peers, earning an "Attractively Valued" rating.
Technical & fundamental data as of Sep 14, 2026.
Open?$21.50
High?$22.39
Low?$21.01
Prev. Close?$21.90
Volume?54.6K
Avg. Volume?67.5K
VWAP?$21.72
Rel. Volume?0.81x
Bid / Ask
Bid?$22.06 × 100
Ask?$30.95 × 100
Spread?$8.89
Midpoint?$26.51
Valuation & Ratios
Market Cap?83.8M
Shares Out?3.8M
Float?1.4M
Float %?41.4%
P/E Ratio?N/A
P/B Ratio?-55.86
EPS?-$22.57
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
Employees
92
Market Cap
83.8M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2024-02-16
Address
4020 STIRRUP CREEK DRIVE
DURHAM, NC 27703
Phone: 919-908-2422
DURHAM, NC 27703
Phone: 919-908-2422
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?61
Piotroski F-Score?0/9Weak
Altman Z-Score?-1.59Distress
Confidence?30%Very Low
Short InterestElevated
Short % of Float?7.52%Elevated
Short Interest?104.3K
Days to Cover?2.1
Free Float1.4M
Avg Daily Volume50.6K
Settlement Date2026-08-31
Financial Health
Current Ratio?1.98Adequate
Quick Ratio?1.31Adequate
Cash Ratio?0.76Adequate
Debt/Equity?-46.58Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score100/100
P/E?N/A▾
P/B?-55.86CHEAP▾
S&P97
P/S?1.94CHEAP▾
Peers100
S&P68
P/FCF?N/A▾
EV/EBITDA?-2.5CHEAP▾
S&P97
EV/Sales?2.99CHEAP▾
Peers100
S&P61
Returns & Efficiency
ROE?5,755.6%STRONG▾
Peers50
S&P97
ROA?-62.9%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-42595729
Enterprise Value?$129.6M
Fundamentals ratios updated end of day